Evaluation of efficacy of buserelin plus nilutamide in Mexican Male patients with advanced prostate cancer

Q4 Medicine

Revista mexicana de urologia Pub Date : 2016-11-01 DOI:10.1016/j.uromx.2016.10.001

R.F. Velázquez-Macías , S. Aguilar-Patiño , R. Cortez-Betancourt , I. Rojas-Esquivel , G. Fonseca-Reyes , N. Contreras-González

{"title":"Evaluation of efficacy of buserelin plus nilutamide in Mexican Male patients with advanced prostate cancer","authors":"R.F. Velázquez-Macías , S. Aguilar-Patiño , R. Cortez-Betancourt , I. Rojas-Esquivel , G. Fonseca-Reyes , N. Contreras-González","doi":"10.1016/j.uromx.2016.10.001","DOIUrl":null,"url":null,"abstract":"<div><h3>Introduction</h3><p>In recent years, total androgen blockade therapy for advanced prostate cancer has been a reasonable option to castration due to the discovery and development of new pharmacologic agents. In this study, our aim was to evaluate the efficacy of the combined treatment of nilutamide plus buserelin and to describe the occurrence of adverse events associated with this treatment.</p></div><div><h3>Material and methods</h3><p>A descriptive, prospective study was conducted. Patients with advanced prostate cancer receiving nilutamide plus buserelin were evaluated at 3, 6, and 9 months. The primary endpoint was the reduction of serum levels of prostate-specific antigen (PSA).</p></div><div><h3>Results</h3><p>One hundred and four patients were included in the study, but only 67 patients had complete information and thus were evaluated in the efficacy analysis: 65 (97.0%) achieved a 50% reduction in PSA level, compared with the baseline value, and 2 patients achieved a decrease <10ng/ml. The combination therapy was well tolerated, given that only 7 patients (6.7%) presented with mild adverse events that did not require treatment suspension or other specific maneuvers.</p></div><div><h3>Conclusions</h3><p>Treatment with nilutamide plus buserelin appears to be safe and effective in controlling tumor activity in advanced prostate cancer patients.</p></div>","PeriodicalId":34909,"journal":{"name":"Revista mexicana de urologia","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2016-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.uromx.2016.10.001","citationCount":"2","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Revista mexicana de urologia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S2007408516300738","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Medicine","Score":null,"Total":0}

引用次数: 2

Abstract

Introduction

In recent years, total androgen blockade therapy for advanced prostate cancer has been a reasonable option to castration due to the discovery and development of new pharmacologic agents. In this study, our aim was to evaluate the efficacy of the combined treatment of nilutamide plus buserelin and to describe the occurrence of adverse events associated with this treatment.

Material and methods

A descriptive, prospective study was conducted. Patients with advanced prostate cancer receiving nilutamide plus buserelin were evaluated at 3, 6, and 9 months. The primary endpoint was the reduction of serum levels of prostate-specific antigen (PSA).

Results

One hundred and four patients were included in the study, but only 67 patients had complete information and thus were evaluated in the efficacy analysis: 65 (97.0%) achieved a 50% reduction in PSA level, compared with the baseline value, and 2 patients achieved a decrease <10 ng/ml. The combination therapy was well tolerated, given that only 7 patients (6.7%) presented with mild adverse events that did not require treatment suspension or other specific maneuvers.

Conclusions

Treatment with nilutamide plus buserelin appears to be safe and effective in controlling tumor activity in advanced prostate cancer patients.

查看原文本刊更多论文

布西林联合尼鲁胺治疗墨西哥男性晚期前列腺癌的疗效评价

近年来，由于新药物的发现和发展，全雄激素阻断治疗晚期前列腺癌已成为去势治疗的合理选择。在这项研究中，我们的目的是评估尼鲁胺加布赛林联合治疗的疗效，并描述与这种治疗相关的不良事件的发生。材料与方法采用描述性、前瞻性研究。晚期前列腺癌患者接受尼鲁胺加布西林治疗，分别在3、6和9个月时进行评估。主要终点是血清前列腺特异性抗原(PSA)水平的降低。结果104例患者纳入研究，但只有67例患者信息完整，因此在疗效分析中进行了评估:65例(97.0%)患者的PSA水平与基线值相比降低了50%，2例患者的PSA水平降低了10 ng/ml。联合治疗耐受性良好，因为只有7例患者(6.7%)出现轻度不良事件，不需要暂停治疗或其他特定操作。结论尼鲁胺联合布西林治疗晚期前列腺癌患者肿瘤活性控制安全有效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Revista mexicana de urologia Medicine-Urology

CiteScore

0.20

自引率

0.00%

发文量

期刊介绍： Revista Mexicana de Urología (RMU) [Mexican Journal of Urology] (ISSN: 0185-4542 / ISSN electronic: 2007-4085) is bimonthly publication that disseminates research by academicians and professionals of the international medical community interested in urological subjects, in the format of original articles, clinical cases, review articles brief communications and letters to the editor. Owing to its nature, it is publication with international scope that disseminates contributions in Spanish and English that are rigorously reviewed by peers under the double blind modality. Neither journalistic documents nor those that lack rigorous medical or scientific support are suitable for publication.